Implantation of a mini-osmotic pump plus stereotactical injection of retrovirus to study newborn neuron development in adult mouse hippocampus.

Adult neurogenesis, a process of generating newborn neurons from adult neural stem cells, is required for brain homeostasis, cognition, and affective behaviors. Deciphering the molecular mechanisms underlying adult neurogenesis will provide valuable insights into the functional integrity of the adult brain and the etiology of neurological disorders. Here, we present an optimized protocol combining stereotactic injection of retrovirus expressing red fluorescent protein to label newborn neurons and implantation of a mini-osmotic pump to investigate newborn neuron development in adult mouse hippocampus. For complete details on the use and execution of this protocol, please refer to Tang et al. (2019).

Use of an implantable pump for controlled subcutaneous insulin delivery in healthy cats.

The aim of this study was to examine the safety and reliability of a research-grade implantable pump for controlled delivery of insulin glargine in cats. For this purpose, a small telemetrically controlled drug delivery pump with a refillable reservoir was implanted into the subcutaneous tissues of the dorsal neck in 10 clinically healthy cats. The reservoir was filled with insulin glargine, and the pump was programmed to deliver four boluses of 0.25 IU/kg, 2-3 weeks apart. As a control, insulin glargine (0.25 IU/kg) was injected SC. Blood glucose and plasma insulin glargine concentrations were measured before each bolus and SC injection and for 8 h afterward. Cats were monitored for signs of discomfort. Pumps were easily implanted and well tolerated by all cats. The experiment was completed in five of 10 cats. In four, the pump failed because of technical reasons; another cat developed severe hypoglycaemia attributable to insulin leakage. Overall, plasma insulin glargine increased after six of eight (75%) initial boluses and after one of 16 (6%) successive boluses. Glucose decreased after seven of eight (88%) initial boluses and after four of 16 (25%) successive boluses. Only the first bolus significantly increased plasma insulin glargine (P = 0.008) and decreased glucose (P = 0.008). Of 20 SC injections, 10 (50%) increased plasma insulin glargine (P <0.001) and 12 (60%) decreased glucose (P <0.001). The pump did not cause discomfort in cats, but life-threatening hypoglycaemia occurred in one. Frequent device problems suggest that the pump needs improvements. Because successive boluses did not increase plasma insulin glargine, this type of insulin may not be appropriate with the pump.

An evaluation of a target-controlled infusion of propofol or propofol-alfentanil admixture for sedation in dogs.

OBJECTIVES: To evaluate sedation quality and cardiorespiratory variables in dogs sedated using a target-controlled infusion of propofol or propofol-alfentanil admixture. METHODS: A total of 60 dogs undergoing diagnostic imaging were randomly assigned to one of three sedation protocols: propofol alone; propofol with a low concentration of 12 µg of alfentanil per mL of propofol; or propofol with a higher concentration of 24 µg of alfentanil per mL of propofol. Target-controlled infusion was initiated at a propofol target concentration of 1·5 µg/mL and increased until lateral recumbency was achieved. Times to adopt lateral recumbency and recover, pulse rate, respiratory rate, oscillometric mean arterial pressure and oxygen saturation were recorded. Quality of sedation onset and recovery were scored. RESULTS: Propofol target at lateral recumbency differed significantly (P=0·01) between groups with median (range) values of 3·0 (1·5 to 5·5), 2·0 (2 to 4·5) and 2·25 (1·5 to 3·5) µg/mL for propofol alone, propofol with the lower concentration of alfentanil and propofol with the higher concentration of alfentanil groups, respectively. Time to lateral recumbency was longer and quality of onset less smooth for the propofol group. Pulse rate change differed significantly (P<0·001) between groups (mean pulse rate change at onset of sedation: propofol group +2 ±24 bpm, low concentration alfentanil group -30 ±24 bpm, higher concentration alfentanil group -26 ±23 bpm). Hypoxaemia (SpO2 <90%) occurred in 1, 3 and 13 dogs, in the propofol group, the low concentration alfentanil group and the higher concentration of alfentanil group, respectively (P<0·001). CLINICAL SIGNIFICANCE: Addition of alfentanil to propofol target-controlled infusion did not confer cardiovascular benefits and, at the higher concentration, alfentanil increased the incidence of hypoxaemia.

Successful use of a gonadotropin-releasing hormone (GnRH) analog for the treatment of tertiary hypogonadism (GnRH deficiency) in a 5-year-old Belgian Blue bull.

A bull was referred for a progressive oligoasthenotheratozoospermia that resulted in a unsuitable seminal quality for the cryopreservation. Breeding soundness evaluation results suggested gonadal dysfunction. Because of the lack of normal ranges for these hormones in the bull, in this study, the hypogonadism and the site of the dysfunction (hypothalamus) were diagnosed by the gonadotropin-releasing hormone (GnRH) stimulation test. The evaluation of pituitary and testicular responsiveness by a GnRH stimulating test revealed a responsiveness of the pituitary and testis, thus a secondary hypogonadism (hypothalamic hypogonadism) was postulated and a therapeutic approach based on the subcutaneous administration of GnRH analog was attempted. An increase in semen volume, concentration and sperm characteristics were detected 9 weeks after the start of the treatment, corroborating the hypothalamic origin of the disease and the useful of the GnRH therapy.

Plasma cortisol concentrations after CIDR insertion in beef cows.

The objective of this study was to show plasma cortisol concentration after treatment with controlled internal drug release (CIDR) in non-suckling beef cows. On day 9 after oestrus, two cows were inserted with CIDR into the vagina for 24 h and the other two cows were treated as a control group. Four days later, the two control cows were treated with CIDR and the other two CIDR-treated cows were used as controls. Cortisol concentrations were determined by ELISA in plasma samples collected before, during and after insertion of CIDR. There was a significant increase in plasma cortisol concentrations (p<0.01) after insertion of CIDR. Mean (± SEM) plasma cortisol concentrations increased from 1.3 ± 0.4 to a peak of 8.8 ± 1.1 ng/ml at 5 h and then decreased to basal concentrations at 7 h after insertion of the device. In conclusion, the insertion of intra-vaginal device causes an increase in plasma cortisol concentrations in beef cows, although the pathophysiological significance of the elevation of cortisol is not known.

Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis.

OBJECTIVE: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). METHODS: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. RESULTS: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with a mean and median follow-up time of 28.9 and 26.3 months, respectively. Overall, at last follow-up 78.8% of eyes were considered visual and the overall mean frequency of uveitis episodes after CSI was 0.09 ± SD 0.08 episodes per month. The most common complications leading to vision loss at last follow-up were persistent uveitis episodes (54%), glaucoma (22%), mature cataracts (16%), and retinal detachment (6%). Persistent uveitis episodes tended to be the highest cause of vision loss in horses with <24 months and >48 months of follow-up. CONCLUSIONS: This study demonstrated the long-term maintenance of vision of horses with ERU implanted with a CSI. The increased vision loss related to uveitis episode of inflammation in eyes after the likely depletion of CsA from the CSI suggests that a repeat CSI may be required at or before 48 months after surgery.

Evaluation of an osmotic pump for fentanyl administration in cats as a model for nondomestic felids.

OBJECTIVE: To evaluate the reliability of an SC implanted osmotic pump (OP) for fentanyl administration in cats and to compare serum concentrations of fentanyl delivered via an OP and a transdermal patch (TP). Animals-8 spayed female cats. PROCEDURES: In a crossover design, cats received fentanyl at 25 microg/h via a TP or an OP. All cats were anesthetized for the pump or patch placement (0 hours) and again when it was removed (96 hours). Venous blood samples were collected for measurement of serum fentanyl concentrations at 0, 6, 12, 24, 36, 48, 72, and 96 hours and at 24 and 48 hours after device removal. After a 3-week washout period, the experiment was repeated with each cat receiving the other treatment. RESULTS: Mean serum fentanyl concentrations at 24, 36, 72, and 96 hours were greater when the OP was used than when the TP was used. Mean residence time and half-life were greater when the TP was used. Fentanyl concentration changed significantly faster in initial and elimination phases when the OP was used. Marked interindividual variation in serum fentanyl concentrations was evident with both administration methods. No adverse effects were evident with either method. CONCLUSIONS AND CLINICAL RELEVANCE: Use of the OP to administer fentanyl to cats resulted in a shorter initial lag phase to a therapeutic serum concentration, higher bioavailability, and faster elimination after removal, compared with use of a TP. These advantages, in addition to the inability of cats to remove the OP, may make OPs useful for fentanyl administration in nondomestic felids.

A novel type of implantable and programmable infusion pump for small laboratory animals.

INTRODUCTION: The iPRECIO (Primetech Corporation, Tokyo, Japan) is a new form of pump for infusing small laboratory animals. The key features of the iPRECIO are that it can be implanted within the animal, it is refillable, and it is programmable. The infusion start-points and end-points are adjustable, infusion rate can be altered, and the infusion solution can be changed after the pump is implanted. In order to confirm the precision of the iPRECIO, in vivo and in vitro experiments were employed. METHODS: In the in vitro experiment, at the excretion rate of 1 microl/h for 336 h, 15 microl/h for 96 h, and 30 microl/h for 120 h, the decrease in each pump weight was used to estimate the actual excretion volume. In the in vivo experiments, the iPRECIO was chronically implanted in rats, angiotensin II was infused, and arterial pressure (AP) was monitored. RESULTS: In the in vitro experiment, the volume of solution excreted from the pump increased with time, and the volume excreted matched the programmed volume. The infusion rate also changed at the scheduled time. In the in vivo experiment, AP increased and decreased on schedule, and a dose-dependent pressor response to angiotensin II occurred. Furthermore, after exchanging saline with angiotensin II, AP increased and decreased on schedule. DISCUSSION: Present data of the in vitro and in vivo experiments indicates that the iPRECIO worked precisely, making it suitable for a variety of experiments involving small laboratory animals.

Evaluation of an implanted osmotic pump for delivery of amikacin to corn snakes (Elaphe guttata guttata).

The risk of accidental envenomation to the handler of venomous snakes during drug administration limits the ability to treat these animals. One commercially available osmotic pump is a miniature self-contained cylindrical implant that operates on the basis of an osmotic pressure difference between the extracellular fluid and the osmotic agent in the pump. Osmotic pumps loaded with amikacin were surgically placed into the coelomic cavity of five adult corn snakes (Elaphe guttata guttata) (group A). Four snakes (group B) received an intramuscular injection of amikacin at 5 mg/kg followed by 2.5 mg/kg q 72 hr for a total of four injections. Plasma concentrations of amikacin were measured in both groups. Renal function was evaluated pre- and posttreatment via scintigraphy with 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) and measurement of plasma uric acid concentrations. Mean (+/- SD) steady state amikacin concentration for group A was 6.9 +/- 1.7 microg/ml (predicted = 8.0 microg/ml), and the measured pump rate was 0.134 +/- 0.017 microl/hr (predicted = 0.130 microl/hr). Mean (+/- SD) peak and trough plasma amikacin concentrations for group B were 22.7 +/- 8.5 microg/ml and 14.3 +/- 7.0 microg/ml, respectively. While neither scintigraphy nor plasma uric acid concentrations indicated toxicity in either group, continuous administration of aminoglycosides may cause nephrotoxicity, and it is unknown whether this delivery method of amikacin would be efficacious in treating bacterial infections in snakes. In addition, due to migration of one pump into the trachea causing asphyxiation and death, these pumps may not be appropriate for intracoelomic placement in corn snakes. Nonetheless, the pumps delivered the drug at a predictable rate and were efficacious in achieving a constant plasma concentration of amikacin at the predicted level. Osmotic pumps may offer a safer alternative to periodic intramuscular injections for drug delivery in venomous or aggressive snakes.

Gonadal steroid hormone modulation of nociception, morphine antinociception and reproductive indices in male and female rats.

The purpose of this study was to examine how gonadal steroid hormones modulate basal nociception and morphine antinociception relative to regulating reproduction in the adult rat. Male and female Sprague-Dawley rats were either gonadectomized (GDX) or sham-gonadectomized (sham); GDX males were implanted subcutaneously with capsules containing testosterone (T), estradiol (E2), dihydrotestosterone (DHT), E2 and DHT, or nothing (0). GDX females received E2, T, or empty (0) capsules immediately after surgery, and vehicle or progesterone (P4) injections at 4-day intervals. Basal nociception and morphine antinociception were tested 28 days after surgery on 50 degrees C and 54 degrees C hotplate tests, and reproductive behavior and physiology were assessed shortly thereafter. There were no significant differences in baseline hotplate latencies among the male treatment groups, but morphine was significantly more potent in sham and GDX+T males than in GDX+0 males. The ability of T to increase morphine's potency was approximated by its major metabolites E2 and DHT, given together but not alone. Baseline hotplate latencies were higher in sham females tested during diestrus than in those tested during estrus. Morphine was significantly more potent in sham females tested during proestrus and diestrus than in those tested during estrus. Baseline hotplate latencies were significantly higher, and morphine was significantly less potent in GDX+E2, GDX+E2/P4 and GDX+T females than in GDX+0 females. All group differences in basal nociception and morphine antinociception observed on the 50 degrees C hotplate test were smaller and generally non-significant on the 54 degrees C hotplate test. Steroid manipulations produced the expected changes in reproductive behaviors and steroid-sensitive organs. These results demonstrate that in adult rats, gonadal steroid manipulations, that are physiologically relevant, modulate (1) basal nociception in females but not males, and (2) morphine's antinociceptive potency in both males and females.

Main vascular changes seen in the saline controls of continuous infusion studies in the cynomolgus monkey over an eight-year period.

The aim of this study was to characterize the main vascular lesions seen in the saline controls in continuous infusion studies in monkeys. Data were collected from 17 studies over an 8-year period (ie, around 50 males and 50 females). The study was restricted to lesions at the injection site, in lungs and at the entry point. It showed that the level of the most severe procedure-related lesions (ie, necrosis with abscess formation at the injection site and at the entry point, thromboemboli and probable infarcts in lungs) was low (<10%). Minor changes such as endothelial hyperplasia and intimal thickening at the injection site, and low-graded interstitial pneumonitis in lungs were the most frequent changes (40 to 50% of the animals). Thrombi at the injection site were present in around 30% in males and 40% in females. The slightly higher incidence of thrombi in females was not explained by a difference of vessel size or by hematological differences. This study permitted an opportunity to harmonise terminology among pathologists and to define the main procedure-related changes and their incidence, which could help pathologists better interpret changes in future infusion studies.

Use of three infusion pumps for postoperative administration of buprenorphine or morphine in dogs.

Results of using an implantable osmotic pump, a preset disposable infusion pump, or a reusable programmable infusion pump for postoperative administration of buprenorphine or morphine in dogs undergoing abdominal surgery are described. Ten dogs underwent abdominal surgery for implantation of vascular access ports. Dogs were given buprenorphine s.c. by use of an implantable osmotic pump (4 dogs), morphine s.c. by use of a preset infusion pump (4), or buprenorphine intra-arterially by use of a programmable infusion pump (2). Dogs were monitored, and serum buprenorphine or morphine concentration was measured for 72 hours after surgery; pumps were removed 48 hours after surgery. Severity of pain was determined by assigning a pain score. The preset infusion pump and the programmable infusion pump resulted in comparable pain relief and sustained serum analgesic concentrations throughout the recovery period. However, the cost of the pumps and other associated factors may limit their use to dogs undergoing invasive surgical procedures expected to result in substantial postoperative pain. The level of analgesia obtained with the implantable osmotic pumps was inconsistent.

Effect of continuous infusion of a GnRH agonist (Buserelin) on ovarian hormone secretion and estrous cycle length in cows.

The importance of the ovarian steroid hormones estradiol and progesterone in the control of luteolysis in domestic ruminants is well established. However, there is a lack of studies specifically investigating the effect of stimulating "physiological" changes in endogenous estradiol or progesterone secretion on subsequent luteolysis. In this study we have stimulated endogenous ovarian hormone secretion by infusion of the GnRH analogue, Buserelin, and have assessed the effect of these changes on the timing of luteolysis. Concentrations of estradiol and progesterone were monitored in plasma samples collected from 6 mature, cyclic, lactating, Friesian cows during a control cycle and during a cycle in which Buserelin was infused via osmotic minipump (8.6 microg/h) for 28 days starting on Day 2 of the cycle. Buserelin infusion had little effect on progesterone secretion but did result in a marked stimulation of estradiol secretion from Days 6 to 10 of the cycle (treated cycle 4.3+/-0.2 pg/mL; control cycle 1.8+/-0.3 pg/mL; P<0.001). In addition, there was a significant advancement in the timing of luteolysis during the Buserelin -infused cycle (Day 19.3+/-0.3 compared with Day 21.3+/-0.4; P<0.01). In this study, we have found that infusion of buserelin caused both a significant stimulation of estradiol secretion from the first follicle and a significant advancement in the timing of luteolysis. We hypothesise that the increased secretion of estradiol may have been involved in causing this advancement of luteolysis.

Subconjunctivally implanted micro-osmotic pumps for continuous ocular treatment in horses.

OBJECTIVE: To evaluate the feasibility of using a subconjunctivally implanted micro-osmotic pump for continuous delivery of medication to the eyes of horses- during a 7-day period. ANIMALS: 4 healthy adult horses. PROCEDURE: With horses restrained in a standing position, micro-osmotic pumps were implanted subconjunctivally in each eye for 7 days. The treatment eye received an atropine-loaded micro-osmotic pump (100 microl of 1.5% atropine), and the contralateral eye received a sterile saline-loaded pump (100 microl of 0.9% NaCl) as a control treatment. Pupil size was measured at 12-hour intervals until values returned to baseline. RESULTS: The micro-osmotic pumps were tolerated and did not migrate or become dislodged. During the 7-day treatment period, pupils were significantly larger in the eyes implanted with atropine-loaded pumps, compared with saline-implanted control eyes. CONCLUSIONS AND CLINICAL RELEVANCE: Micro-osmotic pumps were implanted and removed easily from standing horses and were not associated with complications during the 7-day treatment period. Therefore, subconjunctivally implanted micro-osmotic pumps can potentially be used when treating ophthalmic disease in horses.

Insulin-like growth factor (IGF)-I but not IGF-II promotes lean growth and feed efficiency in broiler chickens.

The efficacy of exogenous IGFs to stimulate growth and modulate protein and fat deposition was examined in a number of broiler chicken lines. From around 600 g body weight the chickens received a continuous infusion of vehicle (0.1 M acetic acid), human recombinant IGF-I or [Gly1]IGF-II at 300 microg/kg body weight per day, or a combined infusion of 150 microg/kg/day of each IGF for 2 weeks. Experiment 1 used commercial broiler female chickens and included measurements of nitrogen balance, Ntau-methylhistidine excretion and muscle protein synthesis rates. In Experiment 2 the same treatments were applied to three experimental lines of chickens selected for high food consumption (relatively fat), high food utilisation efficiency (relatively lean), or at random (control). IGF-I, but not IGF-II, significantly increased growth rate and food utilisation efficiency by around 10-15% in each experiment, an effect which was consistent across all genotypes. Nitrogen balance was significantly increased by IGF-I in Experiment 1 as was carcass nitrogen content in Experiment 2, indicating that the increased growth was in lean tissue. Carcass fat was consistently reduced in chickens receiving IGF-I and was related to the levels of circulating IGF-I (r2 = 0.30, P < 0.01) but not triiodothyronine. Protein synthesis rates were unaffected by treatment and could not account for increased growth rate. However, there was a significant reduction in Ntau-methylhistidine excretion indicating a reduced rate of muscle protein breakdown in IGF-I-treated chickens (1. 56%/day vs 2.05%/day for IGF-I-treated vs controls, P < 0.05). The efficiency of feed utilisation was inversely related to the rate of protein breakdown (r2 = 0.25, P < 0.01). In conclusion, these experiments are the first to report an enhancement of growth and food utilisation efficiency by broiler chickens receiving exogenous IGF-I. Our results show that IGF-I may be important in controlling the growth and efficiency of food utilisation of young chickens at least in part by modulating the rates of protein breakdown.

Superovulation of New Zealand white rabbits by continuous infusion of follicle-stimulating hormone, using a micro-osmotic pump.

A successful method for superovulation of rabbits, which is more time effective than current protocols, has been established and consistently yields large numbers of fertilized ova. Subcutaneous microosmotic pumps were used to administer follicle-stimulating hormone (FSH) over a 3-day period to mature ovarian follicles. The amount of FSH administered was based on baseline serum FSH concentration in unmated New Zealand White does; as determined by radioimmunoassay. Treatment with FSH was followed by intravenous administration of human chorionic gonadotropin (hCG) to enhance ovulation. Hormonally primed does were then mated to mature, fertile bucks. Ova were collected 18 to 20 h after mating. This procedure resulted in an average yield of 37 ova/doe, with a 72.3% fertilization rate. These results were consistent with those published for superovulation using multiple subcutaneous injections of FSH. This method provided a consistent high yield of fertilized ova per doe and required only a simple surgical procedure.

A comparison of two methods of oestrous synchronisation of hair sheep in the tropics.

Two trials were conducted to evaluate the efficacy of oestrous synchronisation procedures in St. Croix White, Barbados Blackbelly hair and Florida Native wool ewes. In Trial 1 (conducted in June), 27 ewes were treated with controlled internal drug release (CIDR) devices for 12 days (CIDR1) and 29 untreated ewes served as controls (CONT). The CIDR devices were removed on the same day that intact rams equipped with marking harnesses were placed with the ewes. Time to oestrus after ram introduction was shorter (P < 0.0001) in CIDR1 than CONT ewes. Within 3 days of ram introduction 100% of CIDR1 ewes but only 37.9% of CONT ewes had been in oestrus (P < 0.0001). Conception rate at first oestrus after ram introduction was 74.1% overall, with no effect (P > 0.10) of treatment, but days to conception were shorter (P < 0.001) in CIDR1 than CONT ewes. Ovulation rate at first oestrus after ram introduction was not different (P > 0.10) between CIDR1 and CONT ewes. The CIDR1 ewes lambed earlier (P < 0.004) in the lambing season than CONT ewes, but there was no difference in the number of lambs born per ewe (P > 0.10). In Trial 2 (conducted in October), 14 St. Croix White ewes were treated with CIDRs as in Trial 1 (CIDR2) and 14 St. Croix White ewes were given two i.m. injections (15 mg) of prostaglandin F2 alpha (PGF) 10 days apart. Intact rams were introduced on the day of CIDR removal or the second PGF injection. The CIDR2 ewes exhibited oestrus earlier (P < 0.01) than PGF treated ewes. The conception rate to breeding at the synchronised oestrus was similar (P > 0.10) between CIDR2 and PGF treated ewes. Progesterone concentration on Day 10 after the synchronised oestrus was not different (P > 0.10) between CIDR2 and PGF treated ewes. These results indicate that oestrous synchronisation procedures can be used in sheep in the tropics without adversely affecting fertility. Due to a lack of seasonal anoestrous these procedures have the potential to be used during all times of the year.

Effect of 48 h treatment with 17 beta-oestradiol or progesterone on follicular wave emergence and synchrony of ovulation in Bos indicus cows when administered at the end of a period of progesterone treatment.

The objective of this study was to determine the effect of treatment with additional progesterone (P4) or 17 beta-oestradiol (E2) at the end of a period of P4 treatment on ovarian follicular development, ovulation time, and plasma gonadotrophin and steroid hormone concentrations of Bos indicus cows. Initially, two injections of PGF2 alpha were given 14 days apart, and at the time of the second injection (Day 0) all cows received a single P4-releasing controlled internal drug release (CIDR) device that was removed 10 days later. Control cows (Group 1, n = 8) received no other treatment. On Day 8, cows in Group 2 (n = 8) and Group 3 (n = 8) received either a s.c. implant containing E2, or a second CIDR device, respectively. All CIDR devices and E2 implants were removed at a similar time on Day 10. Treatment with E2 or P4 delayed mean (+/- SD) time of ovulation (113.1 +/- 25.6 h, 153.4 +/- 44.5 h and 150.8 +/- 25.1 h for Groups 1, 2 and 3, respectively; P < 0.05) and the mean time (+/- SD) of the luteinising hormone (LH) peak (87.4 +/- 24.5 h, 124.3 +/- 45.0 h and 122.3 +/- 25.04 h for Groups 1, 2 and 3, respectively; P < 0.05). Both treatments delayed the mean (+/- SD) day of emergence of the ovulatory follicle (7.7 +/- 3.6 days, 11.3 +/- 1.7 days and 11.1 +/- 1.5 days for Groups 1, 2 and 3, respectively; P < 0.05), and reduced the variability in the day of emergence of the ovulatory follicle (P < 0.05) compared with the control cows. Variability in age and duration of dominance of the ovulatory follicle was greater in control animals compared with treated animals (P < 0.05). Treatment with E2 on Days 9 and 10 did not alter mean concentrations of gonadotrophins in the cows in Group 2 compared with control cows (P > 0.05), whereas treatment of cows with an additional CIDR device resulted in greater mean concentrations of FSH and lesser concentrations of LH on Day 9 (P < 0.05) compared with cows in Groups 1 and 2. By Day 10 mean concentrations of gonadotrophins were similar among cows in all three groups. Concentrations of E2 were less in cows in Group 3 compared with cows in Groups 1 and 2 from Day 9 to Day 11 (P < 0.05). We conclude that treatment with either E2 or P4 can influence the pattern of ovarian follicular development and ovulation in cattle; however, the mechanism of action of the two treatments may differ. Atretogenic treatments for ovarian follicles applied at the end of a period of progesterone treatment did not improve synchrony of ovulation.

Continuous infusion of adrenocorticotropin elevates circulating lipoprotein cholesterol and corticosterone concentrations in chickens.

The purpose of the present study was to investigate the effects of elevated corticosterone (CORT) on circulating lipoprotein cholesterol during a 1-wk period. For this study, 15 commercial broilers were randomly assigned to one of three treatment groups. Group 1 served as the control (CON) and received no treatment, whereas Groups 2 and 3 received subcutaneous mini-osmotic pumps containing either physiological saline (PS) or adrenocorticotropin (ACTH), respectively. The ACTH was delivered at a rate of 8 IU/kg of BW/d. Blood samples were taken at Time 0 (before implants) and on Days 2, 4, and 7 postimplantation. Continuous infusion of ACTH increased plasma glucose, cholesterol, triglycerides, very low density lipoprotein cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and CORT during the postimplantation period. The group treated with ACTH also exhibited a decrease in BW during the last 2 sampling d. There were no differences in any of the serum constituents measured between CON and PS birds, which suggest that CON birds can serve as useful controls. These data suggest that birds given a continuous infusion of ACTH at 8 IU/kg of BW/d can experience changes in plasma lipoprotein cholesterol concentrations along with changes in other blood parameters and may serve as a useful model in accelerated lipoprotein production.